Latest Blog Posts Tagged "Phase III Trial"
December 10, 2018
An interim analysis concluded that the SURE-PD3 trial is unlikely to determine that inosine can slow Parkinson's progression. The trial therefore is ending earlier than planned.
June 29, 2016
Dr. Kevin Biglan reports how the STEADY-PD Phase III trial is progressing and answers questions on calcium and Parkinson's disease.
June 27, 2016
The Safety of Urate Elevation in Parkinson's Disease Phase III study (SURE-PD3) is in the final stage of clinical testing.
January 07, 2016
MJFF, Cynapsus and Intel announce a pilot incorporating wearable devices and "big data" approaches into a trial of a drug to help patients return to "on" from "off" episodes.
September 01, 2015
Based on findings from MJFF-funded research, today the Parkinson Study Group announced an NIH grant for a Phase III trial of inosine, a potential disease-modifying treatment for Parkinson's disease.
November 26, 2014
Isradipine, a high blood pressure medication, will enter Phase III clinical trial testing to determine if it can slow the progression of Parkinson's disease.
October 30, 2014
The FDA has approved Israeli company Intec Pharma Ltd. to carry out a Phase III trial of the Accordion Pill for treatment of Parkinson's. The study is expected to begin in the second half of 2015.
October 20, 2014
A clinical trial of a compound with potential to slow disease progression is recruiting newly diagnosed PD patients not yet in need of symptomatic therapy to test the drug's efficacy.
Podcast: Drug That May Slow Parkinson's Progression Granted $23 Million from NIH for Phase III Testing
March 31, 2014
Tanya Simuni, MD, principal investigator of the STEADY-PD, and MJFF CEO Todd Sherer talk about the study of isradipine, recently granted $23 million from the NIH for Phase III testing.
March 14, 2014
A study in the United Kingdom is testing a drug in treating mild dementia with Parkinson's and comparing clinical scales to measure cognitive impairment.